CYT387, A NOVEL JAK2 INHIBITOR, INDUCES HEMATOLOGIC RESPONSES AND NORMALIZES INFLAMMATORY CYTOKINES IN MURINE MYELOPROLIFERATIVE NEOPLASMS Running Title: Novel JAK2 Inhibitor for MPN
نویسندگان
چکیده
Oregon Health & Sciences University Knight Cancer Institute, Portland, OR 97239, USA Oregon Health & Sciences University School of Nursing, School of Medicine, Department of Radiation Medicine, Portland, OR 97239, USA 3 Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria Oregon Health & Science University Department of Pathology, Portland, OR 97239, USA Howard Hughes Medical Institute 6 YM Biosciences Australia Pty Ltd (formerly Cytopia Research Pty Ltd), 499 St Kilda Rd, Melbourne, VIC 3004 Australia 7 Correspondence: Michael W. Deininger, Hematology and Medical Oncology, OHSU BRB 553, Mailcode L592, 3181 SW Sam Jackson Park Road, Portland, OR 97239. Phone: (503) 494-1603; Fax: (503) 4943688; E-mail: [email protected] *equal contribution Scientific heading: Myeloid Neoplasia Blood First Edition Paper, prepublished online April 12, 2010; DOI 10.1182/blood-2009-05-223727
منابع مشابه
CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms.
Activating alleles of Janus kinase 2 (JAK2) such as JAK2(V617F) are central to the pathogenesis of myeloproliferative neoplasms (MPN), suggesting that small molecule inhibitors targeting JAK2 may be therapeutically useful. We have identified an aminopyrimidine derivative (CYT387), which inhibits JAK1, JAK2, and tyrosine kinase 2 (TYK2) at low nanomolar concentrations, with few additional target...
متن کاملMYELOID NEOPLASIA CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms
1Knight Cancer Institute, Oregon Health & Science University, Portland; 2Department of Radiation Medicine, School of Medicine, School of Nursing, Oregon Health & Science University, Portland; 3Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria; 4Department of Pathology, Oregon Health & Science University, Portland; 5Howard...
متن کاملThe use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy.
BACKGROUND Hypercalcemia of malignancy is a serious complication of cancer that affects patients with and without bone metastases. A single infusion of pamidronate disodium, a nitrogen-containing bisphosphonate, effectively normalizes serum calcium in the majority of patients treated for up to 1 month. Zoledronic acid is a new-generation, heterocyclic nitrogen-containing bisphosphonate and the ...
متن کاملA mutation in the Arabidopsis HYL1 gene encoding a dsRNA binding protein affects responses to abscisic acid, auxin, and cytokinin.
Both physiological and genetic evidence indicate interconnections among plant responses to different hormones. We describe a pleiotropic recessive Arabidopsis transposon insertion mutation, designated hyponastic leaves (hyl1), that alters the plant's responses to several hormones. The mutant is characterized by shorter stature, delayed flowering, leaf hyponasty, reduced fertility, decreased rat...
متن کاملAn antimicrobial helix A-derived peptide of heparin cofactor II blocks endotoxin responses in vivo.
Host defense peptides are key components of the innate immune system, providing multi-facetted responses to invading pathogens. Here, we describe that the peptide GKS26 (GKSRIQRLNILNAKFAFNLYRVLKDQ), corresponding to the A domain of heparin cofactor II (HCII), ameliorates experimental septic shock. The peptide displays antimicrobial effects through direct membrane disruption, also at physiologic...
متن کامل